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Abstract
Background Large observational datasets such as Clinical
Practice Research Datalink (CPRD) provide opportunities
to conduct clinical studies and economic evaluations with
efficient designs.
Objectives Our objectives were to report the economic
evaluation methodology for a cluster randomised con-
trolled trial (RCT) of a UK NHS-delivered public health
intervention for children with asthma that was evaluated
using CPRD and describe the impact of this methodology
on results.
Methods CPRD identified eligible patients using prede-
fined asthma diagnostic codes and captured 1-year pre- and
post-intervention healthcare contacts (August 2012 to July
2014). Quality-adjusted life-years (QALYs) 4 months post-
intervention were estimated by assigning utility values to
exacerbation-related contacts; a systematic review identi-
fied these utility values because preference-based outcome
measures were not collected. Bootstrapped costs were
evaluated 12 months post-intervention, both with 1-year
regression-based baseline adjustment (BA) and without BA
(observed).
Results Of 12,179 patients recruited, 8190 (intervention
3641; control 4549) were evaluated in the primary analysis,
which included patients who received the protocol-defined
intervention and for whom CPRD data were available. The
intervention’s per-patient incremental QALY loss was
0.00017 (bias-corrected and accelerated 95% confidence
intervals [BCa 95% CI] –0.00051 to 0.00018) and cost
savings were £14.74 (observed; BCa 95% CI –75.86 to
45.19) or £36.07 (BA; BCa 95% CI –77.11 to 9.67),
respectively. The probability of cost savings was much
higher when accounting for BA versus observed costs due
to baseline cost differences between trial arms (96.3 vs.
67.3%, respectively).
Conclusion Economic evaluations using data from a
large observational database without any primary data
collection is feasible, informative and potentially
efficient.
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Key Points for Decision Makers
Large observational datasets (such as Clinical
Practice Research Datalink [CPRD]) provide
opportunities to conduct clinical studies with
efficient designs by utilising routinely collected
resource-use data in randomised trials.
Full economic evaluations (i.e. estimation of the cost
per quality-adjusted life-year [QALY]) can feasibly
be conducted alongside such clinical studies by using
a trial-based modelling approach to combine
routinely collected data with supplementary data
from the literature (such as utility values and unit
costs).
This study design may be particularly suited to
interventions that aim to optimise usual care and
where the main clinical outcome is likely to result in
a change in healthcare resource use within primary
or secondary care.
1 Introduction
Economic evaluations are performed alongside clinical
studies to provide information to aid decision makers in
regards to resource allocation. Economic evaluation
requires that costs and outcomes (e.g. quality-adjusted life-
years [QALYs]) are quantified, but the collection of such
data can be both time consuming and costly.
Large observational datasets of routinely collected data
from primary care, hospitals or wider healthcare services
provide opportunities to use existing patient groups and
datasets to perform studies such as randomised controlled
trials (RCTs) and accompanying economic evaluations.
Examples of such databases include Clinical Practice
Research Datalink (CPRD) [1], ResearchOne [2] and
Hospital Episode Statistics (HES) [3]. The logistical ben-
efits of using large databases may be desirable for
researchers, funding bodies looking for studies that use
efficient designs and the National Health Services (NHSs)
within the United Kingdom (UK) in general; such study
designs have been suggested as an approach to enable
patients to be entered into RCTs more quickly than tradi-
tional study designs [4]. The accurate measurement of
patient-level resource-use information for the purpose of
economic evaluation has historically been challenging
when relying on self-reported methods [5] or raw data
extracted from healthcare services [6–8]. These large
observational databases provide a great deal of patient-
level resource-use information, which includes data about
doctors’ visits in clinic or at home, inpatient or outpatient
care and prescribed drugs at the practice level—the type of
data available depends on the database.
It is important to note that implementing a study within
a database without any primary data collection can also
generate some issues that need consideration; for example,
the type and quality of data within these databases depend
on the coding and recording of information at the service
level. However, if a clinical condition or intervention is
hypothesised to have a substantial impact on healthcare
resource use within primary or secondary care, then iden-
tifying these outcomes in a large observational dataset
should be feasible, and this study design could be very
useful, informative and efficient for the clinical study and
economic evaluation.
The PLEASANT (Preventing and Lessening Exacerba-
tions of Asthma in School-age children Associated with a
New Term) trial was a cluster RCT with a primary care-
based intervention evaluated using CPRD [9]. This paper
uses the PLEASANT RCT as a case study to describe the
strengths and limitations of performing an economic
evaluation (cost-per-QALY analysis in this case) using
only data from a large observational database. The full
results of the PLEASANT study are available in the health
technology assessment report [10].
2 Methods
2.1 Clinical Practice Research Datalink (CPRD)
and the PLEASANT Trial
CPRD is the world’s largest validated computerised data-
base of anonymised longitudinal primary care medical
records [11]. At the time of trial recruitment (January to
July 2013), it included 433 contributing practices in Eng-
land and Wales. Records were derived from the Vision IT
General Practice software systems (although CPRD has
reportedly started accepting practices using EMIS software
systems [1]) and contain prescribing and coded diagnostic
and clinical information as well as information on tests
requested, laboratory results and referrals made at or fol-
lowing on from each consultation [12]. Thus, CPRD cap-
tures medical contacts, from prescription request through to
out-of-hours contacts, along with contact reason. This
negates the need to request this information from general
practitioner (GP) practices. CPRD also captures some non-
primary care contacts, such as hospital admissions; how-
ever, the comprehensiveness of this information is uncer-
tain and relies on the relay of information between primary
and secondary care [13].
A previous analysis of data from CPRD suggested there
was an excess number of unscheduled contacts in children
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with asthma following the start of the new school term,
which may in part be explained by decreased usage of
medications over the summer [14]. The aim of the
PLEASANT trial was to assess whether an NHS-delivered
public health intervention (a letter from the GP to par-
ents/carers of school-aged children with asthma) sent in
July 2013 prior to the start of a new school term reduced
the number of unscheduled medical contacts associated
with asthma exacerbation after the school return in
September compared with usual practice (i.e. no letter).
The letter reminded parents to continue their children’s
medication over the school holidays and collect medica-
tions if they were running low (the full letter is presented in
the Electronic Supplementary Material [ESM] appendices,
Fig. S4.1).
The study setting was primary care with practice level
clustering; the recruitment processes have been published
[15]. CPRD identified eligible participants based on pre-
agreed asthma diagnostic codes and predefined inclusion
criteria. The inclusion criteria included school-aged chil-
dren (4–16 years) with a coded diagnosis of asthma, reg-
istered with a GP and receiving asthma medication during
the 12-month period between March 2012 and March 2013.
Patients in the intervention practices were subsequently
screened by the GP to confirm inclusion. Practices ran-
domised to intervention had to send the letter to eligible
patients within the week commencing 29 July 2013; the
control practices did not need to do anything. Further
details about practice and patient recruitment and ran-
domisation are provided in the ESM (Appendix S1.1).
Despite the inclusion criteria, the primary analysis
population were children aged 5–16 years because of the
reported difficulty associated with making an asthma
diagnosis among children below this age [16, 17]; however,
children aged \5 years were examined in a subgroup
analysis as recommended by the Trial Steering Committee.
The period of interest for exacerbations was the new school
term (1 September to 31 December 2013). Resource use
was assessed from 1 August 2013 to 31 July 2014 to
capture any change in resource use in response to the letter
intervention; data 1 year prior to intervention (1 August
2012 to 31 July 2013) were also analysed to allow
adjustment for any baseline differences between trial arms.
2.1.1 Compliance with Ethical Standards
Ethical approval for the study was given by South York-
shire Research Ethics Committee on 25 October 2012
(reference number 12/YH/04). NHS permissions to conduct
the study were obtained for all the Primary Care Trusts
(PCTs) in England and Health Boards in Wales. PLEA-
SANT is Controlled Clinical Trials registered
(ISRCTN03000938).
2.2 Resource Use and Unit Costs
CPRD collect data on the number and type of medical
contacts. As patients may present with multiple problems at
a single contact, and contact reason is not always accu-
rately coded at the practice level, we did not restrict our
analysis to respiratory-related contacts. While not all con-
tacts in children with asthma will be related to their asthma,
we assumed that, because the practices were randomised,
any difference in the number of contacts between trial arms
would be related to the intervention.
An NHS perspective was taken and unit costs were
assigned based on a standardised 2014/15 price year. Unit
costs were assigned according to consultation type (e.g.
surgery visit, hospital admission, etc.). CPRD also includes
a generic entry of ‘other’ tasks, which were assumed to be
unclassified administrative tasks for the purpose of apply-
ing a unit cost. All unit costs were taken from national or
published sources for primary care [18–20], hospital [21]
or drug [22] resource use. All unit costs are presented in the
ESM (Appendixes S1.3 and S1.4, Tables S3.1–3.8),
including the costing of the letter intervention (Table S3.4),
which came to £1.34 per patient.
2.3 Utility Values and the Quality-Adjusted Life-
Year (QALY)
Although the UK National Institute for Health and Care
Excellence (NICE) recommends trials collect preference-
based patient-reported outcome measures (PB-PROMs,
e.g. EuroQoL 5-Dimensions [EQ-5D]) to obtain utility
values for cost-per-QALY analysis [23], PB-PROMs are
not collected routinely by CPRD and were not used within
the PLEASANT trial. A systematic review was used to
identify exacerbation-related utility values [24]; the utility
values used for this analysis [25–27] are described in
Table 1. A larger utility decrement was applied for
exacerbations that resulted in hospital admission (–0.2 vs.
–0.1). It is worth noting that these utility decrements were
based on an adult population because robust estimates in
children are lacking.
CPRD contains no codes to directly determine the
number, severity or duration of acute asthma exacerba-
tions. It was therefore necessary to estimate the number of
asthma exacerbations experienced from the CPRD data
collected. Unscheduled contacts were assumed to represent
an exacerbation (alternative exacerbation proxies and their
limitations are described in the ESM [Appendix S1.2]). To
define unscheduled contacts, a GP adjudication panel
(consisting of three independent GPs) met, reviewed and
defined the coding of the contacts recorded by CPRD as
scheduled, unscheduled or not applicable (irrelevant);
additional information is provided within the ESM
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(Appendix S1.2) and the PLEASANT website [28]. As a
single exacerbation may be associated with more than one
unscheduled contact, we needed to define the number of
exacerbations based on the pattern of unscheduled contacts.
The number of exacerbations and QALYs were calculated
using a Markov assumption. We split the 4-month follow-
up period into weekly cycle periods (17 9 1-week cycles
and one 3-day cycle) and assumed the patient was having
an exacerbation in any cycle that included an unscheduled
contact of any type. Patients experiencing an exacerbation
were assumed to have a utility decrement for the whole
cycle period. The most severe utility decrement for a given
exacerbation (i.e. hospitalised or non-hospitalised), irre-
spective of the number of exacerbations in a week cycle
period, was applied for the whole week. QALYs were then
calculated using the area under the curve (AUC) method
[29].
2.4 Statistical Analysis and Economic Evaluation
For the economic analysis, the per protocol group rather
than the intention-to-treat (ITT) group was chosen to allow
the economic analysis to best reflect the actual resource
implications of the intervention as intended. That is,
children whose parents actually received the letter (i.e.
were not excluded by their GP; note, GPs would be able to
exclude patients from the intervention, as appropriate, if
the intervention were to be rolled out nationally) in the
designated time window for the intervention to have an
effect. ITT groups were assessed as part of the main clin-
ical analysis [9].
The mean number of acute exacerbations per patient was
estimated, and cost per patient was calculated by combin-
ing resource-use estimates with unit costs. Resource use is
based on all ‘tasks’ recorded in CPRD. A statistically
significant difference in resource use and associated costs
was assessed using the t-test assuming unequal variance
(due to the unequal sample sizes between trial arms).
Statistical significance was judged at the two-sided 5%
threshold, unless stated otherwise.
We assumed the intervention would have no impact on
mortality and no impact on utility beyond 4 months
because a previous study found excess medical contacts
associated with the new school year are confined to the
autumn school term (September to December; 4 months)
[14]. Therefore, we expected any quality-of-life improve-
ments from reducing exacerbations associated with the new
school year to fall within the autumn term. However, it is
Table 1 Health-state utility values applied in economic evaluation
Health state Health utility
value
Description of state from source study Measurement Source
Base-case scenario
No exacerbation 0.96 (SD 0.07) Average baseline utility across children (n = 27)
aged 7–18 with GINA severity stage I–III receiving
standard outpatient care in the Netherlands as part
of the control arm of an RCT
EQ-5D child version (completed
by parent for age\12 years).
UK adult TTO valuation set
[27]
Exacerbation not
requiring
hospitalisation
(including ED visits)
–0.10 relative
to no
exacerbation
Adult patients enrolled in a prospective observational
study who have moderate or severe asthma (BTS
rating: 4/5) at baseline and who have experienced
one exacerbation requiring oral steroid treatment
(without hospitalisation) in the previous 4 weeks
(n = 22)
EQ-5D UK adult valuation set [26]
Exacerbation
requiring
hospitalisation
–0.20 relative
to no
exacerbation
Adult patients enrolled in a prospective observational
study who have moderate or severe asthma (BTS
rating: 4/5) at baseline who have experienced one
exacerbation requiring hospitalisation in the
previous 4 weeks (n = 5)
EQ-5D UK adult valuation set [26]
Sensitivity analysis
No exacerbation As per base
case
As per base case As per base case [27]
Any exacerbation –0.216 relative
to no
exacerbation
Patients aged[12 years (including adults) enrolled in
the GOAL study who experienced an exacerbation
(defined as deterioration in asthma requiring
treatment with an oral corticosteroid, or an ED visit
or hospitalisation)
AQLQ values mapped to EQ-5D
(valuation set not stated)
[25]
AQLQ Asthma Quality of Life questionnaire, BTS British Thoracic Society, ED emergency department, EQ-5D EuroQol 5-Dimensions, GINA
Global Initiative for Asthma, RCT randomized controlled trial, SD standard deviation, TTO time trade-off
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possible the letter could have longer-term resource-use
implications that were assessed over the year (e.g. being
prompted to see your doctor, the doctor requesting an
asthma review or picking up a prescription now may
change your resource-use behaviour patterns in terms of
when and how often you visit your GP practice in the
future). Therefore, QALYs were calculated for 4 months
post-intervention and costs were calculated for 1 year post-
intervention. A sensitivity analysis that used a consistent
timeframe for both costs and QALYs was conducted by
analysing consequences only up until the end of December.
Accounting for baseline differences between trial arms
is recommended [30–33] and should be based on patient
characteristics or baseline utility values [30, 33], but, if
these are not sufficiently presented, baseline costs can be
used as a substitute [32]. Unit costs were attached to the
resource use of the patient 1 year before the intervention to
elicit 1-year baseline costs. Patient costs were adjusted by
1-year baseline costs (baseline adjusted [BA]) using boot-
strapped ordinary least squares (OLS) regression models
(1000 replications) with 1-year baseline costs and inter-
vention group as covariates in the model. Nonparametric
bootstrapped estimation was used for unadjusted patient
costs and QALYs (1000 replications). Practice-level
clustering with random effects was accounted for in the
bootstrapped analysis. Unadjusted (observed) and adjusted
(BA) results are reported for mean and incremental values
as well as the bootstrapped standard error (bSE) and bias-
corrected and accelerated confidence intervals (95% BCa
CIs) [34] for all post-bootstrap estimations. For the BA
mean cost estimations (not BA incremental results), the
reported SEs are delta-method SEs, which are appropriate
for adjusted/transformed cost approximations [35], and
normal 95% CIs. The main sensitivity and subgroup anal-
yses are described in Table 2. The point estimate incre-
mental cost-effectiveness ratios (ICERs) were calculated as
the difference in mean cost over difference in mean
QALYs between the letter (CostL; QALYL) and no letter
(CostNL; QALYNL) arms such that:
ICER ¼ CostL  CostNL
QALYL  QALYNL
The ICERs from the bootstrapped (observed and BA)
analysis using 1000 replications were used to create cost-
effectiveness acceptability curves (CEACs) for a range of
decision makers’ willingness-to-pay (WTP) thresholds.
Statistical analysis was performed using Stata version 14
[36].
Table 2 Summary of sensitivity and subgroup analysis
Model aspect
varied
Base-case scenario Sensitivity scenarios Rationale
Unit cost for
contact types
defined as
‘other’
Unit cost of £0.11,
assuming that ‘other’ are
undefined administrative
tasks
Pooled weighted unit cost of £45.58 based on
the recorded resource use for all contacts
and associated unit costs excluding ‘other’
tasks
Whether these ‘other’ consultation types are
administrative is uncertain
Duration of
exacerbation
period
1 week 3 days
2 weeks
The average duration of symptoms for an
exacerbation is uncertain
Utility
decrement
values for
exacerbation
–0.1 (non-hospital) or –0.2
(hospitalisation) for
exacerbation [20]
–0.216 relative to no exacerbation [19] The utility decrement relative to no
exacerbation is uncertain
Type of
contacts
included
All contacts regardless of
whether they are
respiratory related
Respiratory-related contacts Contacts coded as respiratory related are more
likely to be affected by the intervention, but a
large proportion of contacts could not be
coded as respiratory or non-respiratory related
QALY and
cost-
estimation
period
QALYs estimated for 4
months and costs for 1
year post-intervention
QALYs estimated for 4 months and costs for 5
months post-intervention
To assess the shorter term (5 months) cost
implications of the intervention
Age of
population
receiving
intervention
Children aged 5–16 years Children aged\5 years (children aged 4
years)
To assess the cost effectiveness of the
intervention for children aged\5 years
QALY quality-adjusted life-year
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3 Results
3.1 Descriptive Statistics
Of 141 practices (12,179 participants) recruited to the
PLEASANT trial as of July 2013, a total of 70 practices
(5917 participants) were allocated to the ‘letter’ interven-
tion and 71 practices (6262 participants) to ‘no letter’. Of
5917 letter arm participants, 786 were excluded from the
intervention by their GP and six practices (695 partici-
pants) were not eligible for the per protocol group because
the letter was not sent on time or at all. Another ten letter
arm practices (635 patients) and 17 no letter arm practices
(1455 patients) were excluded because CPRD data were
not available for the trial period, because of moving to a
different GP system (i.e. not Vision). The per protocol
group was used for the economic analysis, for which 8608
patients were eligible. Of these, 8190 patients (letter 3641;
no letter 4549) were aged 5–16 years and used as the pri-
mary group for analysis; another 418 patients (letter 160;
no letter 258) were aged \5 years and included in the
subgroup analysis. A practice and patient flow CONSORT
diagram is available in the ESM (Fig. S4.2).
For the primary analysis patient cohort, the mean age
was 10.8 years (median 11.0 years) and 60.4% were male,
both of which were consistent between trial arms (see also
Table 3). The mean number of exacerbations, resource use
and associated costs per patient by classified resource-use
type (i.e. scheduled, unscheduled or ‘not relevant’ con-
tacts), prescription costs and overall costs for 1-year
baseline and follow-up are presented in Table 3. These
results suggest that, at baseline, the letter versus no letter
arm had a statistically significantly higher mean total cost
of care if statistical significance is judged at a 10%
threshold for descriptive purposes (£761 vs. £727, respec-
tively; p = 0.069).
3.2 Incremental Costs and QALY Results
The incremental results used to assess comparative cost
effectiveness are presented in Table 4; the results by trial
arm are presented in the ESM (Table S3.13), as are the
patient resource use and costs by task (e.g. home visits and
consultations) and trial arm (Appendix S2.1,
Tables S3.9–3.12).
For the main unadjusted analysis, the mean observed
cost and QALY was £696.24 and 0.31594 QALYs for the
letter group and £710.98 and 0.31611 QALYs for the no
letter group. For the BA main analysis, the adjusted mean
cost was £684.39 and £720.46 for the letter and no letter
group, respectively (Table S3.13). The incremental mean
QALY difference was –0.00017 (95% BCa CI
–0.00051 to 0.00018) with a mean cost difference of
–£14.74 (95% BCa CI –75.86 to 45.19) or –£36.07 (95%
BCa CI –77.11 to 9.67) for the unadjusted and BA cost
analysis, respectively (Table 4). Although the 95% CIs
cross zero for all incremental outcomes, we can be rea-
sonably confident that the intervention does not result in
large differences in QALYs (the mean difference was
equivalent to a loss of 1.5 h of perfect health) or substantial
additional costs (less than the cost of one additional GP
visit). The results were reasonably consistent in the sensi-
tivity analyses using BA costs, but the subgroup analysis
and some sensitivity analyses using observed costs did not
estimate a mean cost saving (i.e. the intervention was
less effective and more costly under these scenarios)
(Table 4).
3.3 Key Cost-Effectiveness Analysis Results
The cost-effectiveness analysis found there was some
uncertainty regarding the impact of the letter intervention
for both patient benefit and costs to the NHS. The differ-
ences in costs and QALYs from the bootstrapped analysis
can also be visually interpreted from the cost-effectiveness
planes for the unadjusted and adjusted main analysis as
presented in Fig. 1a, b, respectively. Whilst the interven-
tion was cost effective in 93.8% of samples when valuing a
QALY at £20,000 in the BA analysis (Table 4; Fig. 2), it
also resulted in a QALY loss within 82.9% of the boot-
strapped estimates.
The very small QALY loss means the ICER is very large
for all analyses. For example, for the BA main analysis, the
ICER based on the mean point estimates was £217,088 per
QALY, which is the ICER for the cost savings per QALY
forgone, rather than the slightly more common cost per
QALY gained associated with reported ICERs.
The sensitivity analyses showed that the cost-effective-
ness results were sensitive to the assumptions regarding the
costing of ‘other’ contacts, duration and utility decrement
assigned to a period of exacerbation, types of contact
included in the analysis, as well as the period of cost
estimation and if the focus changed to children aged\5
years. The probability of cost effectiveness in the BA
analysis for those aged 5–16 years generally remained
above 62.4% at a WTP threshold (k) of £20,000 per QALY
and above 75.0% when focused on cost savings (rather than
effectiveness; k\£0) of the intervention. The probability of
cost effectiveness in the BA analysis for those aged\5
years was 26.3% (k\£20k) or 33.4% (k\£0) (Table 4).
Whilst more contacts are recorded in the letter arm
(Table 3), these contacts have a lower average cost per
contact, making this intervention cost saving on average in
the analysis focused on those aged 5–16 years.
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4 Discussion
4.1 Implications for Policy and Future Studies
To determine whether conducting economic evaluations
using observational datasets is preferable to using tradi-
tional study designs, we need to consider the efficiency to
researchers of using existing datasets and whether there are
any trade-offs in terms of decision uncertainty.
Raw data extraction can be problematic, particularly in
primary care [6]. For large studies, such as PLEASANT
(with 108 practices with 12 months of data and 8190
patients), using CPRD may be considered an efficient
approach, particularly given that CPRD data are relatively
readily available, it is possible to plan study time horizons
with expected extraction times, and a data dictionary is
available to assess data availability against the needs of the
study. Using data that have already been anonymised by
CPRD also avoids the need for consent from individual
patients, which may be necessary when directly accessing
identifiable data held by practices. This was particularly
efficient in this case because the intervention intended to
optimise usual care, which meant it was not necessary to
obtain individual consent from patients and no action was
needed following randomisation in the control practices.
These aspects may be desirable when commissioning or
designing research studies, which could see these types of
study designs being a part of research objectives from a
funding body perspective.
The information provided by this study design can be
described as informative because a full economic evalua-
tion was possible using the available data. Whilst a number
of assumptions were required to estimate clinical outcomes
from resource-use outcomes, the probability of the inter-
vention being cost saving remained high for the BA anal-
ysis across the sensitivity analyses. In the future, we plan to
extend this work by applying expected value of perfect
information (EVPI) methods [37] to undertake a more
quantitative assessment of the relative value of using rou-
tine data compared with a traditional study design.
4.2 CPRD
The PLEASANT trial was focused on a primary care-based
intervention and so CPRD was ideal for this trial. Within
CPRD, large amounts of primary care resource-use infor-
mation are available, and CPRD also captures some
resource use external to primary care, such as some hos-
pital inpatient and emergency department data. However,
this non-primary care information is not as detailed or as
comprehensive as that available from other datasets such as
HES. For example, CPRD records hospital admissions, but
codes such as HRG-4 (resource grouping codes) are not
available using CPRD but are available within HES. These
codes are particularly useful for the evaluation and costing
of hospital data [38], and empirical research has suggested
that HES outpatient data are ‘‘reasonably valid’’ for
research purposes [39]. However, the reliability of other
aspects of HES data have been questioned [40, 41]. Also,
because information about patients’ secondary care con-
tacts must be manually entered at the practice, this infor-
mation may be incomplete in primary care datasets [13].
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Fig. 2 Cost effectiveness acceptability curve for the letter interven-
tion versus no letter. Note: this graph demonstrates the probability of
cost effectiveness at a range of decision-maker ceiling willingness-to-
pay values for the letter intervention from the main analysis
(unadjusted) and the baseline-cost adjusted main analysis
Economic Evaluations Using Large Datasets
Using linked datasets has been recommended by previous
studies to best assess and evaluate the care pathway and
resource use of patient groups [42, 43], but the use of
linked datasets comes with its own technical and analytical
challenges [44]. However, it is worth noting that a subset of
English practices (reportedly 75%, representing 58% of all
UK CPRD practices) have consented to participate in the
CPRD linkage scheme, which includes linkage with HES
data [13]. HES data were not included in this study because
evidence from Cropper et al. [45] suggests that the majority
of contacts for children with asthma exacerbation would
occur in primary care, and we assumed that secondary care
contacts would be captured in CPRD in most cases.
However, we recognise this as a limitation of the study, and
we may have underestimated the costs of exacerbations
that resulted in secondary care contacts.
There was also an issue with practices changing IT
systems away from the Vision system during the trial
period, which restricted the number of patients included in
the economic evaluation because of data availability. We
would advise researchers designing future studies to con-
sider the possibility of practices dropping out of the dataset
when determining recruitment targets.
Herrett et al. [13] have described the representativeness
and coverage of CPRD for the UK population. In terms of
CPRD coverage, ‘‘The population of active patients (alive
and currently registered) on 2 July 2013 was 4.4 million,
representing 6.9% of the total UK population’’ [13]. They
suggest that CPRD patients are broadly representative of
the UK population in terms of age and sex [46], ethnicity
[47] and body mass index (for most subgroups) [48]. CPRD
practice populations have also been shown to be repre-
sentative of the UK GP population, the exception being a
deficit of children aged 0–4 years and an excess of patients
aged C85 years [49]; therefore, CPRD can be considered
generally representative of our primary patient group,
children aged 5–16 years in the UK. There is also a
question as to whether CPRD practices who know their
data are being collected record activities better, are more
proactive and perhaps offer better care than non-CPRD
practices; however, this is probably true of any GP practice
actively involved in research, so it would also affect studies
using a traditional design. Furthermore, any bias is likely to
be mitigated by the fact that both the quality outcomes
framework (QOF) and payment by results (PbR) are
informed by electronically recorded information within
practices [50, 51], which provides an incentive for non-
CPRD practices to also accurately record activity.
Another issue was that some practices did not imple-
ment the letter intervention, although this is an issue with
trial-based evaluations in general rather than with just
CPRD. This means that our analysis was restricted to the
per protocol group who had data available for the trial
period and sent out the letter as per the protocol. The true
strength of CPRD is the logistical benefits of not having to
perform primary care data collection, which is a major
aspect for a more efficient study design.
4.3 Resource Use and Cost Estimation
Whilst CPRD provides data on resource use for the costing
analysis, a number of assumptions were needed to classify
all the healthcare contacts as scheduled or unscheduled for
the purpose of this study. We also had difficulty classifying
contacts as respiratory related or not, with a large propor-
tion (38%) remaining unclassified. The classification of
resource use beyond that already coded in CPRD results in
uncertainty around the estimates and causes difficulties for
analysis.
We also found that a significant proportion of contacts
(11.4%) were coded as consultation type ‘other’, which
does not provide a clear indication of the activity involved.
We therefore made an assumption regarding the type of
activity that might be coded this way; however, an alter-
native assumption for costing ‘other’ contacts for our
sensitivity analysis made some difference to the probability
that the intervention was cost effective. This change in the
probability of cost-effectiveness was much larger in the
observed than in the BA analysis, suggesting these ‘other’
contacts were included more in the dataset for the letter
than in the no letter group. This bias was controlled for in
the BA analysis, but the uncertainty around the costing of
these ‘other’ events is an issue when using this type of data.
The data recorded in CPRD on consultation duration and
staff mix for each consultation were not considered robust
enough for calculating unit costs. Therefore, we had to
make assumptions using advice from our clinical experts
regarding the likely staff mix and duration of contact for
the purpose of applying unit costs. We also had to make
assumptions regarding the likely severity of asthma exac-
erbations presenting in primary and secondary care.
The costing analysis for prescriptions was also prob-
lematic. A large number of different preparations are used
in the management of asthma, each with a unique product
code. For example, for salbutamol inhalers alone, 17
unique products were prescribed within the dataset. To
keep the prescription cost analysis manageable, we esti-
mated the cost per prescription for the ten most commonly
prescribed products for each drug. This approximation is
not expected to have significantly biased the cost-effec-
tiveness analysis for this study because the absolute cost of
most products prescribed in the management of asthma is
low; however, such assumptions may be problematic for
studies focused on medication usage.
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4.4 Utility Values and QALY Elicitation
Another limitation was that we had to infer the severity,
duration and number of exacerbations experienced by
patients from data on healthcare resource use to assign
utility values, which required several assumptions. For
example, we assumed that any week including one or more
unscheduled healthcare contacts was an exacerbation week.
Under this assumption, two unscheduled contacts occurring
2 days apart may count as 1 or 2 weeks of exacerbation
depending on whether they fall within the same week as
defined in the model. This adds uncertainty to the QALY
estimates and was explored in the sensitivity analysis by
varying the cycle duration from 3 days to 2 weeks. The
extent to which a loss of 0.00017 QALYs (BCa 95% CI:
loss of 0.00051 to a gain of 0.00018 QALYs) equivalent to
a loss of 1.5 h in perfect health (BCa 95% CI: loss of 4.5 h
up to a gain of 1.6 h) can be described as any tangible loss
(change) in quality of life to a person is also a debat-
able aspect as part of this study, thus the focus has been
more on the cost savings of this intervention rather than
cost-effectiveness (i.e. cost per QALY).
The study’s use of routine data alsomeantwe had to rely on
published estimates for the impact of asthma exacerbations on
children rather than measuring utility in the patients them-
selves. The systematic review did not identify any studies that
directly measured exacerbation-related utility decrements in
children using preference-based measures [24]. Other studies
identified estimated utility decrements via mapping, either
subjectively or using unpublished algorithmswith insufficient
details. As a result we used the ‘best available’ data from
adults in the base-case analysis, but this may not accurately
reflect the quality-of-life impact of exacerbations in children
whose experiences of asthma and perspectives on quality-of-
life may differ from those of adults. Identifying utility values
from the literature is not uncommon for economic modelling,
but traditional study designs can collect utility data directly
from patients if needed.
4.5 Statistical Analysis and Economic Evaluation
Previous studies have recommended that baseline resource
use and cost data are collected in clinical studies to account
for baseline cost differences between trial arms [31]. How-
ever, these data are not always collected, and data are often
collected using retrospective self-reporting, which is subject
to recall bias, which can affect the reliability of retrospec-
tively collected resource-use information over long time
horizons (such as 1 year) [5]. There are potential reasons for
controlling for baseline cost differences between trial arms,
particularly because of the primary care cluster design of the
trial [32, 52]; for instance, (1) higher resource use and costs
can be due to actual variations in care or differences in the
accuracy of recording of resource use between practices,
which can result in either artificial or real cost differences
between trial arms; (2) a strong predictor of future resource
use is past resource use, and it may be more difficult to
influence the resource use habits of high resource users
(frequent attenders) [53]; (3) high resource users generally
have higher costs and are by nature able to have larger
changes in resource use and costs than low resource users.
Points (1)–(3) will influence the incremental cost difference
at follow-up between trial arms if these high resource users
are allocated more to one trial arm than the other because of
the cluster design of the trial. For the purpose of discussion,
it is unclear which of the aforementioned points may have
attributed to the statistically significantly higher costs for the
letter group at baseline in our case study; however, whatever
the reason, this aspect was statistically controlled for in the
BA analysis. Therefore, there is reason to consider that the
results from the BA analysis may be a better representation
of the potential economic benefit (cost savings) of the letter
intervention than the unadjusted (observed) economic
analysis.
5 Conclusion
When designing future studies, researchers should assess
the pros and cons of implementing an efficient study design
within a large observational database to decide whether this
design is appropriate and potentially beneficial for their
trial. The main limitation with this approach is the lack of
PB-PROMs on which to base utility estimates and derive
QALYs. The main strengths are the logistical benefits of
not having to do primary data collection, the large amounts
of healthcare contact and drug data available for the pur-
pose of analysis and the readily available resource-use
information prior to intervention, which facilitates baseline
adjustments. As electronic healthcare data evolve and
recording quality improves, these efficient study designs
may become more popular and so will the methodology for
the accompanying economic evaluation.
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